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ABSTRACT
Using photoacoustic microscopy (PAM), we evaluated non-invasively oxygenation and vascularization in
vivo due to multiple myeloma (MM) progression. Mice injected with MM.1S-GFP were monitored with a
ﬂuorescence microscope for tumor progression. In vivo PAM of the cerebral bone marrow quantiﬁed the
total oxygen saturation (sO2). At 28 days after the MM cell injection, the total sO2 had decreased by half in
the developing tumor regions, while in the non-tumor regions it had decreased by 20% compared with
the value at one day post MM injection. The blood vessel density was reduced by 35% in the developing
tumor regions, while in the non-tumor regions it was reduced by 8% compared with the value at one day
post MM injection. Hence, PAM corroborated the development of hypoxia due to MM progression and
demonstrated decreased vascularization surrounding the tumor areas.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy localized
primarily in the bone marrow (BM).1 Together with genetic and
epigenetic changes, the BM microenvironment contributes to
pathogenesis and facilitates MM progression. Novel therapies are
being developed based on interrupting the interactions between
MM cancer cells and the supportive BM microenvironment.1,2
The introduction of new therapeutics that include proteasome
inhibitors has signiﬁcantly improved the survival of MM
patients; however, more than 90% of MM patients still relapse.2
In a growing tumor mass, cancer cell overgrowth is coupled
with insufﬁcient angiogenesis, which results in increasing
regions of lowered oxygenation (hypoxia).3,4 Hypoxia is a
potent factor activating various signaling pathways that con-
tributes to an increased number of immature and leaky blood
vessels, which further facilitate MM cell dissemination.4 An
increase in vascular density in the BM, regulated at least in part
by the hypoxia-inducible factor (HIF-a) pathway, was demon-
strated in myeloma patients during monoclonal gammopathy
of undetermined signiﬁcance (MGUS) to MM progression.5
Hypoxia has been linked to a cancer stem cell-like phenotype
maintaining a slow-cycling proliferation rate of cells,6 and also
linked to treatment resistance in solid tumors as well as in MM.6
Thus, hypoxia is a negative prognostic factor for treatment efﬁ-
cacy and patient survival, demonstrating a potentially high ther-
apeutic index.7 However, the evaluation of hypoxia in the tumor
microenvironment largely relies on invasive methods, leading to
an inevitable change of the targeting microenvironment. The
current gold standard for measuring oxygen partial pressure in
solid tumors is a polarographic microelectrode.8 Other
approaches to measure tumor oxygen levels include electron
paramagnetic resonance oximetry, nuclear magnetic resonance
spectroscopy, and positron emission tomography using nitroi-
midazole or 64Cu-ATSM. One of the most common indirect
measurements of oxygenation is performed only ex vivo by
examining the expression of endogenous markers of hypoxia,
such as HIF-1a,9 or by examining the cellular uptake of agents
reduced in a hypoxic environment, such as pimonidazole.4,10
Photoacoustic microscopy (PAM) is an emerging tech-
nique,11,12 widely applied in biomedical research ranging from
the study of the mechanism of diseases, including a variety of
cancers and stroke, to the study of functional connectivity of
the brain.13 One notable advantage of PAM is the fact that
hemoglobin is an endogenous absorption contrast; hence it
enables label-free in vivo measurement of oxygen saturation
(sO2) of hemoglobin in red blood cells (RBCs) without disrupt-
ing the microenvironment. Furthermore, owing to its high sen-
sitivity to optical absorption and the weak acoustic scattering in
tissue, PAM possesses such a high imaging sensitivity that it
enables monitoring a single ﬂowing RBC with safe laser expo-
sure.14 Thus, compared with other methods, PAM potentially
provides a more accurate description of the oxygenation as well
as vascularization of the microenvironment of the tumor.11,12
In this study, using optical-resolution photoacoustic micros-
copy (OR-PAM),15 we measured the spatial distribution of sO2
of blood vessels in the BM in the mouse skull. With its high
spatial resolution of a few micrometers, OR-PAM can precisely
image the sO2 distribution in this microenvironment. We also
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monitored the sO2 changes induced by MM cell progression in
the BM.
Results
In order to directly monitor and image the oxygenation level
and blood vessel density during MM progression in the BM in
vivo, we used an OR-PAM imaging system demonstrated in a
schematic diagram in Fig. 1A. We performed OR-PAM within
the frontal bone of the skull in MM-bearing SCID mice
(Fig. 1B), which allowed to visualize and measure oxygen
saturation of hemoglobin in RBCs in the BM with minimal
invasiveness to the tumor microenvironment. Fig. 2A shows
ﬂuorescence microscope images of the MM tumor develop-
ment in the BM of the skull after injection of MM1s-GFP cells,
as well as PAM of the sO2 and the vascularization in the normal
and tumor BM areas as shown in Fig. 2B. Quantiﬁcation of the
ﬂuorescence images shows that the tumor size within the tumor
regions increased over 4 weeks after the cell injection (Fig. 2C).
The total sO2 levels in normal and tumor areas at 14 and 28
days post cell injection were measured by PAM. It was found
that the total sO2 levels decreased over time, while the level of
total sO2 in adjacent normal BM areas did not change over
time. At day 28, the total sO2 level in the developing tumor
regions decreased to an average of 50% § 15% of the value at
one day post MM injection, while in the non-tumor regions the
total sO2 level decreased to 88% § 16% (Fig. 2Di). The total
sO2 level was shown to be inversely correlated with the tumor
burden (Fig. 2Dii). Additionally, at day 28, the averaged sO2
level in the developing tumor regions decreased to an average
of 87% § 8% of the value at one day post MM injection, while
in the non-tumor regions the averaged sO2 level slightly
increased to 102% § 7%.
Moreover, we quantiﬁed the vascularization (vessel density)
in normal and tumor areas of the BM after the injection of MM
cells. A signiﬁcant reduction of blood vessel density was
observed in the tumor region, while the level of vascularization
did not change in normal BM areas. The blood vessel density
in the developing tumor regions decreased to an average of
65% § 12% of the value at one day post MM injection, while in
the non-tumor regions, it decreased to 92% § 15% (Fig. 2Ei).
The level of vascular density was shown to be inversely corre-
lated with the tumor burden (Fig. 2Eii).
Discussion
Based on our results, we obtained clear evidence that the total
sO2 levels in the MM cell proliferation regions were signiﬁ-
cantly lower than in the normal (non-tumor affected) regions.
The localized and gradual decrease of the total sO2 level in the
tumor regions is considered to indicate a corresponding
decrease in the total amount of oxygen, which in turn is consid-
ered to naturally induce hypoxia in the region. Therefore, our
results suggest that the hypoxia was developed by the prolifera-
tion of the MM cells, which is in agreement with previously
published studies.4,6 Unlike other invasive techniques, PAM
provided real-time visual evidence for the development of hyp-
oxic and low vascularization regions due to tumor develop-
ment, without disrupting the microenvironment. Based on our
results, the blood vessel density in the tumor regions decreased
Figure 1. Optical-resolution photoacoustic microscopy (OR-PAM) for in vivo imaging of oxygenation and vascularization in the bone marrow. (A) Schematic diagram of
the OR-PAM imaging system. AL, acoustic lens; CL, correction lens; DAQ, data acquisition; DM, dichroic mirror; FC, ﬁber coupler; M, mirror; ND, neutral density ﬁlter; PD,
photodiode; PH, pinhole; PR, prism; SMF, single-mode ﬁber; SO, silicone oil; UT, ultrasonic transducer. (B) Imaging regions in the mouse skull.
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as the tumor developed. This fact indicates a decrease of the
blood ﬂow rate of these regions, unless the blood velocity
increased to offset the effect of the reduction of the blood vessel
density, which is unlikely. Furthermore, the fact that the aver-
aged sO2 level decreased more in the tumor developing regions
indicates a decrease in the difference between the arterial and
venous oxygen concentration, assuming the oxygen extraction
rate remained at the same level. Therefore, our results reason-
ably indicate a more hypoxic condition in the tumor developing
regions, which is also predicted by the general formula describ-
ing oxygen consumption in tissue. However, a direct correla-
tion between the hypoxic condition in the microenvironment,
the reduction in the total or averaged sO2 level and blood vessel
density needs to be established.
In this study, we did not clarify the reason for the slight
reductions of the total sO2 level and blood vessel density in the
normal region, which are thought to be caused by the surgical
operations in the experiment. Speciﬁcally, the relatively long-
term monitoring or/and the frequent incision of the scalp of
the mouse for the imaging window could induce the slight
physiologic change in the blood vessels in the BM. However,
the results for the total sO2 level and blood vessel density in the
tumor region also included the same effect as the normal
region, so we believe our conclusions were not affected. To pre-
vent the undesirable effect of repeated incision, we could moni-
tor each mouse at only a single but different time point.
We also found that the vascularization in the tumor mass
decreased 4 weeks post MM cell injection, which conﬂicts with
the current state of knowledge. Angiogenesis, new blood vessel
formation from existing vasculature, is one of the best-
described cause-effect consequences of tumor hypoxia, and
plays a pivotal role in tumor progression in cancer.16 It was pre-
viously reported that vascular density in the BM increased in
myeloma patients during MGUS to MM progression.17 Fur-
thermore, monitoring the microvessel density in the BM dem-
onstrated that high-grade angiogenesis at diagnosis was
predictive of poorer response to high-dose induction therapy in
newly diagnosed patients, and contributed to poor prognosis in
myeloma patients.18 The differences between our ﬁndings and
those elsewhere in the literature need to be further explored.
For future work, by taking advantage of the desirable charac-
teristics of PAM, namely, its minimal invasiveness, high spatial
resolution, high speed, high sensitivity, and functional imaging
capability, we can naturally extend it to evaluating the efﬁcacy
of therapeutic drugs targeting MM cells. PAM will give us a
more direct indication of the relationship between the effective-
ness of the drugs and hypoxia.
Materials and methods
MMmouse model
Severe combined immune deﬁciency (SCID) mice (female, 8-
weeks old) were obtained from Envigo. Approval for these
studies was obtained from the Animal Studies Committee at
Washington University in St. Louis. The experiments were exe-
cuted in compliance with institutional guidelines and regula-
tions. MM.1S used in this manuscript was freshly obtained
from American Type Culture Collection (ATCC) and charac-
terized by ATCC based on the karyotype and expression of
cluster of differentiation (CD) markers, receptors and light
chain immunoglobulin. MM.1S were genetically engineered to
express green ﬂuorescent protein (GFP) as described previ-
ously.16 Cells were cultured in RPMI-1640 medium (Corning
CellGro), supplemented with 10% fetal bovine serum (Life
Technologies/Gibco), 2 mmol/l of L-glutamine, 100 U/ml of
penicillin, and 100 mg/ml of streptomycin (CellGro) at 37C
and 5% CO2 in a humidiﬁed tissue culture incubator (NuAire).
The cells are routinely tested for mycoplasma using the Plas-
moTest kit (InvivoGen) and according to the manufacturer’s
protocol. For the study, 2 mice were injected intravenously
(IV) via the tail vein with 4£106 MM.1S-GFP per mouse. The
injected MM.1S dominantly home to the bone marrow in the
whole body, including the skull bone marrow, as described in
the previous research.4
Imaging of MM cells in vivo
To monitor the tumor progression, the mouse brain was
imaged with a wide ﬁeld ﬂuorescence microscope (FluoView
FV1000, Olympus) using 4X or 10X objectives. To measure the
ﬂuorescence of GFP tagged to MM cells, a standard ﬁlter set
was used (NIBA3: excitation ﬁlter 470–495 nm, emission ﬁlter
510–550 nm). The imaging region was within the frontal bone,
where most of the skull bone marrow is located (Fig. 1B).4,17
We monitored the tumor progression by measuring at several
time points: 1, 14 and 28 days after MM.1S-GFP cell injection.
During the imaging, the mice were under inhalational anesthe-
sia with 1.5% isoﬂurane (Isothesia). The scalp of the mouse was
surgically incised to form a ﬂap through which the skull was
imaged, but the skull remained intact. After each monitoring,
the ﬂap was stitched closed.
Photoacoustic imaging
To measure the photoacoustic signal and the sO2 level of RBCs
in the blood vessels of the mouse brain, we used our previously
developed OR-PAM (Fig. 1A).15 The system consisted of 2
diode-pumped solid-state lasers for photoacoustic excitation
with 2 different wavelengths (InnoSlab, Edgewave, for 559 nm,
and SPOT-10–200–532, Elfolight, for 532 nm). The 2 laser
beams with different wavelengths were combined through a
dichroic mirror, whose transmission and reﬂection rates were
selected so that 559 nm light passed through and 532 nm light
was reﬂected. During imaging, the 2 laser beams sequentially
irradiated the target. The repetition rate of each laser was
10 kHz. To detect the photoacoustic signal, the system used an
ultrasonic transducer with a 50 MHz central frequency (V214-
BB-RM, Olympus). To acquire 2-dimensional images, the sys-
tem used 2 motorized translational stages, which enabled 2-
dimensional raster scanning. The step sizes for imaging were
2.5 mm along the fast axis and 5 mm along the slow axis, and
imaging a 4 mm by 6 mm area took around 10 minutes. The
lateral resolution of this system could reach 2.6 mm (full width
at half maximum) when a smaller step size was used.15
sO2 imaging in vivo
We acquired the photoacoustic signal excited at the 2 differ-
ent wavelengths to calculate the sO2 level at each pixel.
15
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OR-PAM imaging was performed on the same day and over
the same imaging region as for the ﬂuorescence microscope.
As during imaging by the ﬂuorescence microscope, the mice
were under inhalational anesthesia with isoﬂurane during
OR-PAM imaging. Also as before, the scalp of the mouse
was retracted, but its skull remained intact.
Analysis of tumor progression, oxygenation, and blood
vessel density
To evaluate tumor progression and oxygenation based on the
images acquired by the ﬂuorescencemicroscope andOR-PAM sys-
tem, we deﬁned 2 comparable regions of interest (ROI) for
Figure 2. The sO2 level and blood vessel density are inversely correlated with the tumor burden. (A) Images of sO2 levels acquired by OR-PAM and the corresponding
ﬂuorescence microscopy images. The mouse brain was imaged at Day 1, Day 14, and Day 28 after intravenous injection of MM cells. Scale bars: 1 mm. (B) Designated
regions of interest (ROI) of mouse 1 and mouse 2 used for analysis denoted as normal areas, regions A and B, and tumor areas, regions C and D. (C) Tumor progression
evaluated as the tumor area (mm2) measured at Days 1, 14, and 28 post MM cell injection (mean§ SD), nD 4. (Di) Comparison of average relative total sO2 level between
tumor and normal regions over the course of 4 weeks and normalized to Day 1 post MM injection (mean § SD), n D 4. (Dii) Correlation between the oxygenation (total
sO2) and the tumor area (mm
2) with correlation coefﬁcient R2 D 0.8096. (Ei) Comparison of average blood vessel density between tumor and normal regions over the
course of 4 weeks and normalized to Day 1 post MM injection (mean § SD), n D 4. (Eii) Correlation between the blood vessel density and the tumor area (mm2) shows a
correlation coefﬁcient R2D 0.7757.
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quantiﬁcation: One was the tumor region, which included the area
where the tumor had developed most signiﬁcantly, based on the
GFP signal intensity at 28 days after MM cell injection (regions C
andD in Fig. 2A). The other was a normal region, which was desig-
nated as the area located as far as possible from all tumor regions
within the ﬁeld of view (regions A and B in Fig. 2A). In all normal
regions, we conﬁrmed that much weaker ﬂuorescence signals were
detected in the normal regions. For each mouse, we selected 2
tumor regions and 2 corresponding normal regions (Fig. 2B). To
evaluate the tumor burden, we calculated the area of the tumor
within the tumor regions at different time points. The area of the
tumor within tumor regions was deﬁned as the group of pixels of
the ﬂuorescence image whose brightness was higher than twice the
average brightness of the normal regions. After co-registering the
ﬂuorescence and photoacoustic images based on the structure of
blood vessels, we also evaluated the total sO2 level, the averaged
sO2 level, and blood vessel density in the deﬁned ROIs. The total
sO2 level within each ROI was calculated as the summation of the
sO2 levels of all pixels of the imaged blood vessels. The averaged
sO2 level within the ROI was calculated as the average of the sO2
levels of all pixels of the imaged blood vessels. The blood vessel den-
sity was calculated as the ratio of the number of pixels of the imaged
blood vessels to that of each ROI.
Statistical analysis
The data were expressed as mean § standard deviation. Results
were analyzed using Two Way ANOVA for statistical signiﬁ-
cance and were considered signiﬁcantly different for a P value
less than 0.05.
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